{"name": "Proteostasis Therapeutics",
 "permalink": "proteostasis-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/proteostasis-therapeutics",
 "homepage_url": "http://www.proteostasis.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": null,
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@proteostasis.com",
 "phone_number": "617-225-0096",
 "description": "",
 "created_at": "Mon Jun 22 07:30:58 UTC 2009",
 "updated_at": "Fri Oct 21 02:39:57 UTC 2011",
 "overview": "\u003Cp\u003EProteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body\u00e2\u20ac\u2122s protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body\u00e2\u20ac\u2122s natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer\u00e2\u20ac\u2122s Disease and Huntington\u00e2\u20ac\u2122s Disease. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       46],
      "assets/images/resized/0005/0038/50038v2-max-150x150.png"],
     [[250,
       77],
      "assets/images/resized/0005/0038/50038v2-max-250x250.png"],
     [[374,
       116],
      "assets/images/resized/0005/0038/50038v2-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Mark",
      "last_name": "J. Enyedy",
      "permalink": "mark-j-enyedy",
      "image": null}},
   {"is_past": false,
    "title": "President and Chief Scientific Officer",
    "person":
     {"first_name": "Peter",
      "last_name": "H. Reinhart",
      "permalink": "peter-h-reinhart",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$45M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.reuters.com/article/idUS91076+25-Aug-2008+BW20080825",
    "source_description": "Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs",
    "raised_amount": 45000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2008,
    "funded_month": 8,
    "funded_day": 25,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "HealthCare Ventures",
         "permalink": "healthcare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/9268/49268v1-max-150x150.jpg"],
             [[250,
               34],
              "assets/images/resized/0004/9268/49268v1-max-250x250.jpg"],
             [[290,
               40],
              "assets/images/resized/0004/9268/49268v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Biosciences",
         "permalink": "fidelity-biosciences-2",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0005/0044/50044v1-max-150x150.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-250x250.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Genzyme Ventures",
         "permalink": "genzyme-ventures",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0002/8655/28655v1-max-150x150.png"],
             [[155,
               52],
              "assets/images/resized/0002/8655/28655v1-max-250x250.png"],
             [[155,
               52],
              "assets/images/resized/0002/8655/28655v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novartis Venture Funds",
         "permalink": "novartis-ventures",
         "image":
          {"available_sizes":
            [[[150,
               14],
              "assets/images/resized/0004/4137/44137v1-max-150x150.png"],
             [[215,
               21],
              "assets/images/resized/0004/4137/44137v1-max-250x250.png"],
             [[215,
               21],
              "assets/images/resized/0004/4137/44137v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "790 Memorial Drive, Suite 103",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": 42.3595196,
    "longitude": -71.1156913}],
 "milestones":
  [{"description": "stands to make up to $50 million from a collaboration with Dublin biotech Elan Corp",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 25,
    "source_url": "http://www.masshightech.com/stories/2011/05/23/daily29-Proteostasis-forms-lucrative-drug-discovery-deal-with-Elan.html",
    "source_text": null,
    "source_description": "Proteostasis forms lucrative drug discovery deal with Elan",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Proteostasis Therapeutics",
      "permalink": "proteostasis-therapeutics"}},
   {"description": "Elan Corporation PLC (ELN) Makes Investment in Proteostasis Therapeutics, Inc. as Part of $50 Million Neurodegenerative Drug Discovery Partnership ",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 25,
    "source_url": "http://www.biospace.com/news_story.aspx?StoryID=221848\u0026full=1",
    "source_text": "",
    "source_description": "Elan Corporation PLC (ELN) Makes Investment in Proteostasis Therapeutics, Inc. as Part of $50 Million Neurodegenerative Drug Discovery Partnership ",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Proteostasis Therapeutics",
      "permalink": "proteostasis-therapeutics"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        101],
       "assets/images/resized/0005/0039/50039v1-max-150x150.jpg"],
      [[250,
        169],
       "assets/images/resized/0005/0039/50039v1-max-250x250.jpg"],
      [[450,
        304],
       "assets/images/resized/0005/0039/50039v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}